These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22890175)

  • 1. [Proton-pump inhibitor therapy and small bowel bacterial contamination].
    Hamvas J
    Orv Hetil; 2012 Aug; 153(33):1287-93. PubMed ID: 22890175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind placebo-controlled randomized trial on probiotics in small bowel bacterial overgrowth in children treated with omeprazole.
    Hegar B; Hutapea EI; Advani N; Vandenplas Y
    J Pediatr (Rio J); 2013; 89(4):381-7. PubMed ID: 23796359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
    Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW
    Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.
    Di Stefano M; Malservisi S; Veneto G; Ferrieri A; Corazza GR
    Aliment Pharmacol Ther; 2000 May; 14(5):551-6. PubMed ID: 10792117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.
    Lombardo L; Foti M; Ruggia O; Chiecchio A
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):504-8. PubMed ID: 20060064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.
    Scarpellini E; Gabrielli M; Lauritano CE; Lupascu A; Merra G; Cammarota G; Cazzato IA; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2007 Apr; 25(7):781-6. PubMed ID: 17373916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin.
    Corazza GR; Ventrucci M; Strocchi A; Sorge M; Pranzo L; Pezzilli R; Gasbarrini G
    J Int Med Res; 1988; 16(4):312-6. PubMed ID: 3169375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.
    Lauritano EC; Gabrielli M; Scarpellini E; Ojetti V; Roccarina D; Villita A; Fiore E; Flore R; Santoliquido A; Tondi P; Gasbarrini G; Ghirlanda G; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2009; 13(2):111-6. PubMed ID: 19499846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test.
    Biancone L; Vernia P; Agostini D; Ferrieri A; Pallone F
    Curr Med Res Opin; 2000; 16(1):14-20. PubMed ID: 16422030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
    Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
    Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.
    Scarpellini E; Giorgio V; Gabrielli M; Filoni S; Vitale G; Tortora A; Ojetti V; Gigante G; Fundarò C; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1314-20. PubMed ID: 23740443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth.
    Su T; Lai S; Lee A; He X; Chen S
    J Gastroenterol; 2018 Jan; 53(1):27-36. PubMed ID: 28770351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-absorbable antibiotics and small bowel bacterial overgrowth.
    Corazza GR; Sorge M; Strocchi A; Benati G; Di Sario A; Treggiari EA; Brusco G; Gasbarrini G
    Ital J Gastroenterol; 1992; 24(9 Suppl 2):4-9. PubMed ID: 1486197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.
    Lauritano EC; Gabrielli M; Lupascu A; Santoliquido A; Nucera G; Scarpellini E; Vincenti F; Cammarota G; Flore R; Pola P; Gasbarrini G; Gasbarrini A
    Aliment Pharmacol Ther; 2005 Jul; 22(1):31-5. PubMed ID: 15963077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term proton pump inhibitor therapy leads to small bowel bacterial overgrowth as determined by breath hydrogen and methane excretion.
    Sieczkowska A; Landowski P; Gibas A; Kamińska B; Lifschitz C
    J Breath Res; 2018 Mar; 12(3):036006. PubMed ID: 29182524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics.
    Cuoco L; Montalto M; Jorizzo RA; Santarelli L; Arancio F; Cammarota G; Gasbarrini G
    Hepatogastroenterology; 2002; 49(48):1582-6. PubMed ID: 12397741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor.
    Sieczkowska A; Landowski P; Zagozdzon P; Kaminska B; Lifschitz C
    J Pediatr; 2015 May; 166(5):1310-1312.e1. PubMed ID: 25681195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management.
    Rao SSC; Bhagatwala J
    Clin Transl Gastroenterol; 2019 Oct; 10(10):e00078. PubMed ID: 31584459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
    Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
    Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
    Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
    Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.